FYRIFER 



therapy coiipared to physically- 

 induced fever, 676j effect on 

 allergy, 675; in balanitis, 

 178; in buboes, 178; colitis, 

 6^6; in dementia paralytica, 

 217, 2UO; diptheria, 69I4; in 

 dematoses, 510; in enteric 

 fevers, ^7h; in epilepsy, 217; 

 in gonorrhea, I6I, 171, 178; 

 in neuritis, retrobulbar, 768; 

 in neuro- syphilis, I63, 171, 

 181, 217; in poliomyelitis, 263, 

 66I1; in psoriasis, 171, 178; 

 psychoses, 217; schizophrenia, 

 217, 227, 2i40; sclerosis, mul- 

 tiple, 712, 76I; staphylococcic 

 infections, 178; tabes, l67; 

 typhus and paratyphus, 533j 

 vulvovaginitis, 171 

 phenobarbital before administration 

 prevents leukocytosis, 269 



PYEOGENS, I423, 723, 729, See alsor 

 Piromen, Polysaccharides and 

 specific bacteria 

 amino acid synthesis in media, 



effect on prodn. , 218 

 antipyrogenic principle, in bac- 

 terial cultures, 237 

 bacterial, Ii03; assay for minimal 

 dosage, 773; French bio-assay 

 635; for potency of hermorrhage- 

 producing prepns., 38O 

 biology of, symposium, 758 

 blood, lipids, changes after, 358 

 blood, for transfusion, report, 

 1435; reactions from unpooled 

 plasma, 36O; incidence of, in 

 multiple sclerosis, 513 

 chemistiy of, 298, 379, ^4714, 511, 

 581, 67I4, 700 



connective tissue mast cell 

 response to. See: Elromen 



contaminants in biologic pro- 

 ducts, I429, i499; in apparatus, 

 3II4 



effects (of E. coli, E. typhosa , 

 Proteus , B. pyocyanus and B. 

 abortus equi j on rabbit, m~use, 

 horse, man, 511; of ur ethane on 

 temperature, 578; changes in 

 blood lipids, 358 



359 



E. tyghosa, purified, effect of 

 intravenous inj., I4I46; mini- 

 mum, lethal and toxic dosages, 

 392; combination with B. 

 tularense increases toTerance 

 to the latter alone, 7i|6 



gastric depression by, 355, 6OO 



gelation, of media, 379 



isolation. See pyrogens, prep- 

 arations; Bacteria (under 

 specific names) 

 from coliform of Salmonella 

 organisms, 751 



panting, thermal, inhibited by, 

 670 



preparations from various 

 species, 709; of safe in- 

 fusion fluids, 2146; method 

 and test, 383; simple method 

 for detecting, 6I48 



properties and biologic effects - 

 literature survey, 1855-;, 623 



Pseudomonas aeruginosa , prepara- 

 tions and test, 377, 383. 

 See Pircmen, Polysaccharide 



reducing sugars (in Ps, 



aeruginosa , E. typEosa, and B. 

 subtilis ) , 14 30 ~ 



removal from protein hydroly- 

 sates, 14314; from penicillin, I432 



review, 28I4 



synposium, 7I49, 7514 



thermostability, I432 



tolerance to toxic activity, I47O, 

 I47I, 5140, 702, 733; abolition 

 by reticuloendothelial 

 blockade (typhoid pyrogen), 

 I4I4I 

 contaminants, cause of danger in 

 saline fluids, 39; in medi- 

 cinal solution, 149;- preven- 

 tion,by chlorobenzene, 

 dichloro-prepn. of ethylene 

 oxide, 758; in penicillin, 

 I46O 

 dose, minimal, for rabbits, ; 



1(03; for man, 773 

 effects, ACTH-like effect, 66I, 

 715, 7I42, 77I1, 775; aug- 

 mentation of activity by 



plasma, 523, 591, 716; by 

 whole blood, 7I4I4; of pyrexin, 

 in inflammation, 597; 



